Payment overview · 2025
General Payments
$442.94
8 reported records · 6 companies
Healthcare provider profile · identity verified
Jay E Reinberg, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AVENTURA, FL · NPI 1073559480
Verified facts
What the public records show
CMS Open Payments records show Jay E Reinberg, M.D. received $442.94 in general payments during 2025 across 8 reported records.
Janssen Scientific Affairs, LLC accounted for 62.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $278.53 | 62.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.48 | 13.7% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $31.07 | 7.0% | 1 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $25.00 | 5.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.00 | 5.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.86 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $442.94 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Scientific Affairs, LLC | $278.53 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $44.79 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $31.07 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
98 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 37 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 306 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 212 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 195 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 184 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 65 |
| Alprazolam | Alprazolam | 150 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 48 |
| Losartan Potassium | Losartan Potassium | 138 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 38 |
| Ozempic | Semaglutide | 129 | 24 |
| Lorazepam | Lorazepam | 119 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 30 |
| Gabapentin | Gabapentin | 100 | 30 |
| Azithromycin | Azithromycin | 98 | 63 |
| Eliquis | Apixaban | 98 | 23 |
| Tramadol Hcl | Tramadol Hcl | 98 | 28 |
| Clonazepam | Clonazepam | 96 | 33 |
| Mounjaro | Tirzepatide | 85 | suppressed |
| Metformin Hcl | Metformin Hcl | 83 | 25 |
| Trazodone Hcl | Trazodone Hcl | 81 | 27 |
| Omeprazole | Omeprazole | 79 | 27 |
| Sertraline Hcl | Sertraline Hcl | 77 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 20 |
| Famotidine | Famotidine | 64 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 44 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 22 |
| Prednisone | Prednisone | 57 | 31 |
| Temazepam | Temazepam | 55 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 16 |
| Montelukast Sodium | Montelukast Sodium | 54 | 15 |
| Ezetimibe | Ezetimibe | 53 | 19 |
| Amoxicillin | Amoxicillin | 52 | 43 |
| Bupropion Xl | Bupropion Hcl | 49 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 18 |
| Methylprednisolone | Methylprednisolone | 47 | 37 |
| Lisinopril | Lisinopril | 44 | 13 |
| Cefdinir | Cefdinir | 43 | 36 |
| Furosemide | Furosemide | 43 | 13 |
| Nifedipine Er | Nifedipine | 41 | 14 |
| Synthroid | Levothyroxine Sodium | 41 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 29 |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 37 |
| Torsemide | Torsemide | 37 | 13 |
| Mirtazapine | Mirtazapine | 36 | 11 |
| Allopurinol | Allopurinol | 35 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | 11 |
| Folic Acid | Folic Acid | 29 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 11 |
| Hydrocortisone | Hydrocortisone | 27 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 19 |
| Simvastatin | Simvastatin | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 21 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 15 |
| Mupirocin | Mupirocin | 23 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Wegovy | Semaglutide | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Tadalafil | Tadalafil | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $442.94 · 8 records | Janssen Scientific Affairs, LLC | ABRYSVO, AREXVY, COMIRNATY, Cleerly Ischemia, Cleerly Labs, GEMTESA, PREVNAR 20, SHINGRIX, Senza, TREMFYA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error